US epilepsy drug delay
LONDON - GLAXOSMITHKLINE PLC and Valeant Pharmaceuticals International say they may have to wait an extra three months for the US regulatory review of their potential epilepsy treatment ezogabine. The two companies said on Tuesday that the US Food and Drug Administration has extended its target date under the Prescription Drug User Act to review ezogabine to Nov 30 from Aug 30.
Read more on Straits Times
You must log in to post a comment.